These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 21817958)

  • 1. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to ocular histoplasmosis syndrome.
    Nielsen JS; Fick TA; Saggau DD; Barnes CH
    Retina; 2012 Mar; 32(3):468-72. PubMed ID: 21817958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization in ocular histoplasmosis.
    Hu J; Hoang QV; Chau FY; Blair MP; Lim JI
    Retin Cases Brief Rep; 2014; 8(1):24-9. PubMed ID: 25372202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.
    Ehrlich R; Ciulla TA; Maturi R; Kheradiya NS; Hrisomalos N; Shulman S; Guess MG; Coyle E; Harris A
    Retina; 2009; 29(10):1418-23. PubMed ID: 19898179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis.
    Schadlu R; Blinder KJ; Shah GK; Holekamp NM; Thomas MA; Grand MG; Engelbrecht NE; Apte RS; Joseph DP; Prasad AG; Smith BT; Sheybani A
    Am J Ophthalmol; 2008 May; 145(5):875-8. PubMed ID: 18321466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of intravitreal antivascular endothelial growth factor therapy for the management of choroidal neovascularization in pseudoxanthoma elasticum.
    Myung JS; Bhatnagar P; Spaide RF; Klancnik JM; Cooney MJ; Yannuzzi LA; Freund KB
    Retina; 2010 May; 30(5):748-55. PubMed ID: 19996818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis.
    Cionni DA; Lewis SA; Petersen MR; Foster RE; Riemann CD; Sisk RA; Hutchins RK; Miller DM
    Ophthalmology; 2012 Feb; 119(2):327-32. PubMed ID: 22133795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
    Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
    Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
    Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
    Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia.
    Wakabayashi T; Ikuno Y; Gomi F
    Retina; 2011 May; 31(5):880-6. PubMed ID: 21242860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
    Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
    Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration.
    Ladas ID; Chatziralli IP; Kotsolis AI; Douvali M; Georgalas I; Theodossiadis PG; Rouvas AA
    Ophthalmologica; 2012; 228(2):93-101. PubMed ID: 22571933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F
    Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum.
    Finger RP; Charbel Issa P; Schmitz-Valckenberg S; Holz FG; Scholl HN
    Retina; 2011; 31(7):1268-78. PubMed ID: 21386758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.
    Ruiz-Moreno JM; Montero JA; Arias L; Araiz J; Gomez-Ulla F; Silva R; Piñero DP
    Retina; 2010; 30(10):1609-15. PubMed ID: 20856171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks: one year of follow-up.
    El Matri L; Kort F; Bouraoui R; Karim B; Chebil A; Chaker N
    Acta Ophthalmol; 2011 Nov; 89(7):641-6. PubMed ID: 21155980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
    Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.